Related Experiment Video

Updated: Mar 20, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC

Alan P Fields1, Syed A Ali1, Verline Justilien1

  • 1a Department of Cancer Biology , Mayo Clinic , Jacksonville , FL , USA.

Small Gtpases
|June 2, 2016
PubMed

Insights

Targeting Protein Kinase Cι (PKCι) offers a promising new strategy for treating KRAS-driven lung adenocarcinoma. Novel drug combinations involving PKCι inhibitors may significantly improve outcomes for patients with this deadly cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Lung cancer is the leading cause of cancer death in the US, with KRAS-driven lung adenocarcinoma (KRAS LADC) being a particularly lethal subtype.
  • Mutant KRAS activates oncogenic Protein Kinase Cι (PKCι), which drives tumor growth, invasion, and maintains cancer stem cell properties in KRAS LADC.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting Protein Kinase Cι (PKCι) in KRAS-driven lung adenocarcinoma.
  • To evaluate novel drug combinations involving PKCι inhibitors for the treatment of KRAS LADC.

Main Methods:

  • The study focuses on the role of PKCι as an oncogenic effector in KRAS LADC.
  • Investigated the efficacy of PKCι inhibitors, both as monotherapy and in combination treatments.

Main Results:

  • PKCι is identified as a key oncogenic effector in KRAS LADC, promoting tumor progression and maintaining tumor-initiating cells.
  • PKCι inhibitors demonstrate promise as therapeutic agents.

Conclusions:

  • Targeting PKCι, particularly through novel drug combinations, represents a promising therapeutic strategy for KRAS LADC.
  • These approaches may lead to improved clinical management and patient outcomes for KRAS LADC.
Keywords:
Protein Kinase Ciotalung adenocarcinomaoncogenic Krastherapeutic targeting

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K